IOL Chemicals and Pharmaceuticals (BSE:524164) - Hisse Senedi Fiyatı, Haberler ve Analizler

524164 Stoklara Genel Bakış

IOL Chemicals and Pharmaceuticals Limited, Hindistan'da ve uluslararası alanda farmasötik ve kimyasal ürünler üretmekte ve satmaktadır.

Şirket hakkında

524164 temel anali̇z
Kar Tanesi Skoru
Değerleme	5/6
Gelecekteki Büyüme	3/6
Geçmiş Performans	1/6
Finansal Sağlık	6/6
Temettüler	3/6

Ödüller

Adil değer tahminimizden 47% daha düşük bir oranda işlem görüyor

Kazançların yılda 22.19% oranında artması öngörülüyor

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

1.24% temettüsü serbest nakit akışları tarafından iyi karşılanmıyor

IOL Chemicals and Pharmaceuticals Limited Rakipler

Themis Medicare

BSE:530199

₹24.2b

Amrutanjan Health Care

BSE:590006

₹22.2b

TTK Healthcare

BSE:507747

₹21.8b

SMS Pharmaceuticals

NSEI:SMSPHARMA

₹25.5b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti IOL Chemicals and Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	₹403.85
52 Haftanın En Yüksek Seviyesi	₹537.05
52 Haftanın En Düşük Seviyesi	₹333.00
Beta	0.83
11 Aylık Değişim	-10.73%
3 Aylık Değişim	-0.44%
1 Yıllık Değişim	-6.05%
33 Yıllık Değişim	-26.96%
5 Yıllık Değişim	102.08%
Halka arzdan bu yana değişim	931.55%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	524164	IN Pharmaceuticals	IN Pazar
7D	7.0%	2.6%	2.3%
1Y	-6.0%	59.1%	37.9%

Getiri vs. Endüstri: 524164 geçen yıl % 59.1 oranında getiri sağlayan Indian Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: 524164 geçen yıl % 37.9 oranında getiri sağlayan Indian Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 524164's price volatile compared to industry and market?
524164 volatility
524164 Average Weekly Movement	6.8%
Pharmaceuticals Industry Average Movement	6.3%
Market Average Movement	6.3%
10% most volatile stocks in IN Market	9.4%
10% least volatile stocks in IN Market	4.0%

İstikrarlı Hisse Senedi Fiyatı: 524164 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: 524164 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1986	2,777	n/a	www.iolcp.com

IOL Chemicals and Pharmaceuticals Limited, Hindistan'da ve uluslararası alanda farmasötik ve kimyasal ürünler üretmekte ve satmaktadır. Şirket, ibuprofen lizinat ve ibuprofen sodyum gibi aktif farmasötik bileşenler (API) ve metformin, fenofibrat, lamotrijin, klopidogrel bisülfat, pantoprazol, gabapentin, levetirasetam, parasetamol vb. dahil olmak üzere diğer API'ler sunmaktadır.

IOL Chemicals and Pharmaceuticals Limited Temel Bilgiler Özeti

IOL Chemicals and Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
524164 temel i̇stati̇sti̇kler
Piyasa değeri	₹23.71b
Kazançlar(TTM)	₹1.19b
Gelir(TTM)	₹20.72b

20.0x

F/K Oranı

1.1x

P/S Oranı

524164 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
524164 gelir tablosu (TTM)
Gelir	₹20.72b
Gelir Maliyeti	₹13.90b
Brüt Kâr	₹6.82b
Diğer Giderler	₹5.64b
Kazançlar	₹1.19b

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	20.19
Brüt Marj	32.92%
Net Kâr Marjı	5.72%
Borç/Özkaynak Oranı	2.0%

524164 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

1.2%

Mevcut Temettü Verimi

22%

Ödeme Oranı

524164 Stoklara Genel Bakış

Ödüller

Risk Analizi

IOL Chemicals and Pharmaceuticals Limited Rakipler

BSE:530199

₹24.2b

BSE:590006

₹22.2b

BSE:507747

₹21.8b

NSEI:SMSPHARMA

₹25.5b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

IOL Chemicals and Pharmaceuticals Limited Announces Resignation of Vikas Vij as Chief Executive Officer, Effective 30 September 2024

Investor sentiment improves as stock rises 21%

IOL Chemicals and Pharmaceuticals Limited Announces Resignation of Sandhya Mehta as Independent Director

Full year 2024 earnings: EPS and revenues miss analyst expectations

IOL Chemicals and Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 09, 2024

Full year 2024 earnings: EPS and revenues miss analyst expectations

Recent updates

IOL Chemicals and Pharmaceuticals Limited Announces Resignation of Vikas Vij as Chief Executive Officer, Effective 30 September 2024

Investor sentiment improves as stock rises 21%

IOL Chemicals and Pharmaceuticals Limited Announces Resignation of Sandhya Mehta as Independent Director

Full year 2024 earnings: EPS and revenues miss analyst expectations

IOL Chemicals and Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 09, 2024

Full year 2024 earnings: EPS and revenues miss analyst expectations

IOL Chemicals and Pharmaceuticals Limited, Annual General Meeting, Aug 23, 2024

IOL Chemicals and Pharmaceuticals Limited to Report Q4, 2024 Results on May 14, 2024

Price target increased by 15% to ₹517

IOL Chemicals and Pharmaceuticals Limited Announces CDE, China Approved Metformin Hydrochloride

IOL Chemicals and Pharmaceuticals Limited Approves Closing of M/S Iol Global Limited, Uk, Wholly Owned Subsidiary of the Company

IOL Chemicals and Pharmaceuticals Limited Approves Closing of M/S Iol Global Limited, Uk, Wholly Owned Subsidiary of the Company

IOL Chemicals and Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 06, 2024

Second quarter 2024 earnings released: EPS: ₹6.45 (vs ₹2.71 in 2Q 2023)

New major risk - Revenue and earnings growth

IOL Chemicals and Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 08, 2023

Investor sentiment improves as stock rises 17%

IOL Chemicals and Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 09, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Price target increased by 13% to ₹510

IOL Chemicals and Pharmaceuticals Receives Cep for Paracetamol to Export in European Market

Full year 2023 earnings: EPS exceeds analyst expectations

Investor sentiment improves as stock rises 19%

Upcoming dividend of ₹4.00 per share at 1.3% yield

Third quarter 2023 earnings released: EPS: ₹4.05 (vs ₹6.82 in 3Q 2022)

IOL Chemicals and Pharmaceuticals Limited Declares Interim Dividend for the Fiscal Year 2023, Payable Before 8 March 2023

IOL Chemicals and Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 07, 2023

Investor sentiment improved over the past week

Second quarter 2023 earnings released: EPS: ₹2.71 (vs ₹5.26 in 2Q 2022)

Price target increased to ₹575

IOL Chemicals and Pharmaceuticals Limited Receives EDQM Certification to Supply Pantoprazole Sodium Sesquihydrate API in European Market

IOL Chemicals and Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 14, 2022

Full year 2022 earnings released: EPS: ₹28.56 (vs ₹76.21 in FY 2021)

IOL Chemicals and Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 09, 2022

Full year 2022 earnings released: EPS: ₹28.56 (vs ₹76.21 in FY 2021)

Now 20% undervalued

IOL Chemicals and Pharmaceuticals Limited Announces Executive Changes

IOL Chemicals and Pharmaceuticals Limited to Report Q4, 2022 Results on May 30, 2022

Price target increased to ₹575

IOL Chemicals and Pharmaceuticals Limited Commences the Commercial Production of 'Paracetamol' with Installed Capacity of 1,800 MTPA Along with Backward Integration of Para Amino Phenol (PAP) with Effect from 22 April 2022

Investor sentiment improved over the past week

Now 22% undervalued after recent price drop

Investor sentiment improved over the past week

Now 23% undervalued after recent price drop

Upcoming dividend of ₹4.00 per share

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

IOL Chemicals and Pharmaceuticals Limited Declares Interim Dividend for the Financial Year 2021-222, Payable Before 5 March 2022

IOL Chemicals and Pharmaceuticals Limited to Report Q3, 2022 Results on Feb 04, 2022

Upcoming dividend of ₹2.00 per share

President of Project recently sold ₹3.5m worth of stock

First quarter 2022 earnings released: EPS ₹11.41 (vs ₹22.30 in 1Q 2021)

Full year 2021 earnings released: EPS ₹76.21 (vs ₹63.51 in FY 2020)

Joint MD & Whole Time Director has left the company

IOL Chemicals and Pharmaceuticals Limited Appoints Sanjay Chaturvedi as Chief Executive Officer

Investor sentiment improved over the past week

New 90-day low: ₹659

Third quarter 2021 earnings released: EPS ₹19.54 (vs ₹17.22 in 3Q 2020)

IOL Chemicals and Pharmaceuticals Limited to Report Q3, 2021 Results on Feb 10, 2021

Ind-Swift Labs' Promoters Reportedly Sound Out PEs to Sell Their Stake